Coeptis Therapeutics Bolsa (NASDAQ: COEP)

Últimas noticias sobre Coeptis Therapeutics (NASDAQ:COEP) Bolsa

Coeptis Therapeutics

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Movers

Trading Ideas

ARKR

AURA

BLRX

CHEK

CMCT

COEP

IDAI

LINC

MGOL

NINE

RSVR

Conoce las acciones que lideran el premercado tras movimientos clave: Check-Cap sube un 52,2% gracias a nueva patente.

Las acciones de Check-Cap suben un 52%; 20 acciones que se están moviendo antes de la apertura del mercado

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings, Inc. - Warrants

Needham analyst Laura Martin reiterates Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) with a Buy and maintains $21 price target.

News

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Viant Technology, Maintains $21 Price Target

JP Morgan analyst Jimmy Bhullar upgrades Reinsurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) from Neutral to Overweight and raises the price target from $232 to $237.

Upgrades

JP Morgan Upgrades Reinsurance Gr to Overweight, Raises Price Target to $237

Needham analyst Mike Cikos reiterates Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Buy and maintains $28 price target.

CLBT

Needham Reiterates Buy on Cellebrite DI, Maintains $28 Price Target

Needham analyst Laura Martin reiterates Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Buy and maintains $20 price target.

MGNI

Needham Reiterates Buy on Magnite, Maintains $20 Price Target

Jones Trading analyst Justin Walsh downgrades Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) from Buy to Hold.

Downgrades

MNPR

Jones Trading Downgrades Monopar Therapeutics to Hold

Needham analyst Mayank Tandon maintains Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) with a Buy and lowers the price target from $45 to $28.

NCNO

Needham Maintains Buy on Ncino, Lowers Price Target to $28

Jones Trading analyst Justin Walsh downgrades BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) from Buy to Hold.

Jones Trading Downgrades BioLine Rx to Hold

HC Wainwright &amp; Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) from Neutral to Neutral.

GALT

HC Wainwright & Co. Reiterates Neutral on Galectin Therapeuticsto Neutral

Jefferies analyst Ashley Helgans maintains PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) with a Hold and lowers the price target from $101 to $80.

Jefferies Maintains Hold on PVH, Lowers Price Target to $80

SVCO

Silvaco's Victory TCAD Solution Adopted By ProMOS Technologies For Next-Gen Silicon Photonics Development

HC Wainwright &amp; Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) with a Buy and maintains $10 price target.

ELTX

HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $10 Price Target

Leggett & Platt To Sell Aerospace Products Group to Tinicum for $285 M, After-tax Cash Proceeds Are Expected To Be Approximately $240M

Jefferies analyst Julien Dumoulin-Smith initiates coverage on CenterPoint Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) with a Buy rating and announces Price Target of $42.

Initiation

Jefferies Initiates Coverage On CenterPoint Energy with Buy Rating, Announces Price Target of $42

CME Group Q1 Average Daily Volume Up 13% YoY, March ADV Up 27% YoY

Jefferies analyst Stephen Volkmann downgrades Timken (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKR#NYSE">TKR</a>) from Buy to Hold and lowers the price target from $90 to $70.

Jefferies Downgrades Timken to Hold, Lowers Price Target to $70

IBG: 267% &#x7C; <a href="https://www.benzinga.com//node/44603539">Innovation Beverage Group Expands U.S. Reach With Republic National Distribution Company Distribution Deal</a>
&nbsp;
SPWH: 63% &#x7C; <a href="https://www.benzinga.com//node/44594851">Sportsman's Warehouse Holdings shares are trading higher after the company reported better-than-expected Q4 financial results.</a>
&nbsp;
NCNO: -36% &#x7C; <a href="https://www.benzinga.com//node/44594847">NCino shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results and issued Q1 and FY26 guidance below estimates.</a>

SPWH

Market-Moving News for April 2nd

After 6 weeks of continued whole body application of QRX003, the subject's skin remains almost completely healed demonstrating the durability of ongoing daily treatment with the product. In addition, the patient has continued to have no requirement for previously necessary medications such as antibiotics, antivirals, antihistamines and glucocorticoids.

QNRX

Quoin Reports Additional Clinical Data From Ongoing Investigator Pediatric Netherton Syndrome Study; Reveals Continued Clear Visual Evidence Of Almost Completely Healed Skin After 6 Weeks Treatment

Award marks Bowman's fifth consecutive ADA-related contract for pedestrian infrastructure enhancements in the city

Contracts

BWMN

Bowman Wins $2.2M Contract To Design Over 1,200 ADA Curb Ramps In Philadelphia

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>)</h3>
<ul>
<li>Dividend Yield: 6.94%</li>
<li>B of A Securities analyst Lisa Lewandowski upgraded the stock from Neutral to Buy and increased the price target from $55 to $65 on Dec. 6, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Barclays analyst Gaurav Jain maintained an Underweight rating and raised the price target from $45 to $46 on Nov. 6, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Recent News: On Jan. 30, the company posted upbeat quarterly sales.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0402">latest MO news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0402"><img loading="lazy" decoding="async" width="858" height="755" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02042845/image-21.png" alt="" class="wp-image-852766" style="width:527px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02042845/image-21.png 858w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02042845/image-21-300x264.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02042845/image-21-768x676.png 768w" sizes="(max-width: 858px) 100vw, 858px" /></a></figure>
<h3 class="wp-block-heading">Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)</h3>
<ul>
<li>Dividend Yield: 8.96%</li>
<li>Deutsche Bank analyst George Hill downgraded the stock from Hold to Sell and cut the price target from $11 to $9 on Feb. 28, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Truist Securities analyst David Macdonald maintained a Hold rating and cut the price target from $13 to $12 on Jan. 31, 2025. This analyst has an accuracy rate of 68%</li>
<li>Recent News: On March 6, Walgreens announced it entered into a definitive agreement to be taken private by an entity affiliated with Sycamore Partners for $10 billion.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0402">latest WBA news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0402"><img loading="lazy" decoding="async" width="922" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02042917/image-22.png" alt="" class="wp-image-852768" style="width:593px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02042917/image-22.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02042917/image-22-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02042917/image-22-768x696.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>)</h3>
<ul>
<li>Dividend Yield: 10.92%</li>
<li>Piper Sandler analyst Michael Lavery maintained a Neutral rating and lowered the price target from $8 to $7 on Feb. 26, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Barclays analyst Brandt Montour maintained an Equal-Weight rating and cut the price target from $8 to $7 on Nov. 7, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On Feb. 25, B&amp;G Foods posted better-than-expected quarterly earnings.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest BGS <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0402">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0402"><img loading="lazy" decoding="async" width="920" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02042949/image-1-4.png" alt="" class="wp-image-852769" style="width:565px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02042949/image-1-4.png 920w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02042949/image-1-4-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02042949/image-1-4-768x698.png 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44600914/unifirst-blackberry-and-3-stocks-to-watch-heading-into-wednesday">UniFirst, BlackBerry And 3 Stocks To Watch Heading Into Wednesday</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Markets

Wall Street's Most Accurate Analysts Give Their Take On 3 Defensive Stocks With Over 6% Dividend Yields

Over the past week, Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) are down 20% and 15%, respectively, as crypto markets await the impact of <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44603859/bitcoin-braces-for-trump-tariff-announcement-short-term-optimism-has-the-upper-hand-expert">President Trump&#8217;s tariff announcements</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1724</td>
<td>$25.6 billion</td>
<td>+0.8%</td>
<td>-15.9%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001233&nbsp;&nbsp;</td>
<td>$7.26 billion</td>
<td>-3.3%</td>
<td>-20.3%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.057391</td>
<td>$3.1 billion</td>
<td>-2.4%</td>
<td>-19.2%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Nebraskangooner noted that SHIB's recent breakout was a fakeout, with many altcoins hitting resistance and retracing
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> (per request) Pretty nasty fake break out.. many other alts have rejected resistance and headed back to the lows from here. <a href="https://t.co/cJmyHHahgh">pic.twitter.com/cJmyHHahgh</a>
&mdash; Nebraskangooner (@Nebraskangooner) <a href="https://twitter.com/Nebraskangooner/status/1907170918079635544?ref_src=twsrc%5Etfw">April 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto chart analyst Ali Martinez <a href="https://x.com/ali_charts/status/1907171359811383352">sees</a> Dogecoin trading near support, with the TD Sequential indicator flashing a buy signal—suggesting a potential bullish reversal.
Trader Byzantine General <a href="https://x.com/ByzGeneral/status/1907212687957790790">remains</a> bullish on meme coins with strong brand recognition, predicting they could be forming cycle bottoms.
Statistics: Shibburn data shows 115.9 million SHIB coins have been removed from circulation over the past 24 hours, increasing the burn rate by 104,201.4%. 
One transaction burned 92.6 million SHIB around nine hours ago. 
IntoTheBlock data shows SHIB large transaction volume and daily active addresses down by 53.3% and 32.8%, respectively. Transactions greater than $100,000 declined from 74 to 54.
DOGE long liquidations declined from $1.72 million to $1.43 million on Tuesday.
Read Next:&nbsp;
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44456360/dogecoin-shiba-inu-up-3-and-flashing-bullish-signals-is-a-rally-coming">Dogecoin, Shiba Inu Up 3% And Flashing Bullish Signals—Is A Rally Coming?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Why Are Dogecoin, Shiba Inu Down Over 15% In The Past Week?

Press Releases

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Biotech

General

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Health Care

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

Coeptis (NASDAQ: COEP) Accelerates Growth with Strategic Partnerships and Innovation

ALNY

AMZN

AVGO

BURU

GOOGL

MSFT

NVDA

REGN

RPRX

SMMT

VRTX

ABVC BioPharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Annovis Bio

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroBiologics

FibroGen

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kezar Life Sciences

OSR Holdings

OS Therapies

Passage Bio

Pluri

Rallybio

RenovoRx

Tenax Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Comments

Coeptis Therapeutics

Noticias

Últimas noticias sobre Coeptis Therapeutics (NASDAQ:COEP) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL